Lipid nanoparticles as drug/gene delivery systems to the retina

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 2, 2013, Pages 173-188

  Del Pozo Rodríguez, Ana ^a   Delgado, Diego ^a   Gascón, Alicia R ^a   Solinís, Maria Ángeles ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CARVEDILOL; CILIARY NEUROTROPHIC FACTOR; CISPLATIN; DEXAMETHASONE; DIGOXIN; EYE DROPS; FLUOCINOLONE ACETONIDE; GAMMA CYCLODEXTRIN; GANCICLOVIR; METHOTREXATE; METHYLPREDNISOLONE; SAQUINAVIR; SOLID LIPID NANOPARTICLE; TOBRAMYCIN; TRIAMCINOLONE ACETONIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; VERTEPORFIN;

AUTOCLAVE; BIOCOMPATIBILITY; BLOOD RETINA BARRIER; COACERVATION; CYTOMEGALOVIRUS RETINITIS; DIABETIC MACULAR EDEMA; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ELECTROSPRAY; ENDOTHELIUM; GENE DELIVERY SYSTEM; GENE THERAPY; HUMAN; IONTOPHORESIS; LIPOSOMAL DELIVERY; LYMPHOMA; MICROEMULSION; POSTERIOR EYE CHAMBER; RETINA; RETINA MACULA EDEMA; RETROLENTAL FIBROPLASIA; REVIEW; SUPERCRITICAL FLUID; SUPERCRITICAL FLUID EXTRACTION; UVEITIS;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; LIPIDS; NANOPARTICLES; RETINA; RETINAL DISEASES;

EID: 84875018489     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0128     Document Type: Review

References (167)

1. del Amo, E.M., & Urtti, A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today. 13:135-143, 2008.
2. Thrimawithana, T.R., Young, S., Bunt, C.R., Green, C., and Alany, R.G. Drug delivery to the posterior segment of the eye. Drug Discov. Today. 16:270-277, 2011.
3. Seyfoddin, A., Shaw, J., & Al-Kassas, R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 17:467-489, 2010.
4. Idrees, F., Vaideanu, D., Fraser, S.G., Sowden, J.C, and Khaw, P.T. A review of anterior segment dysgeneses. Surv. Ophthalmol. 54:213-231, 2006.
5. Geroski, D.H., & Edelhauser, H.F. Drug delivery for posterior segment eye disease. Invest. Ophthalmol. Vis. Sci. 41:961-964, 2000.
6. Urtti, A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 58:1131-1135, 2006.
7. Liu, Z., Zhang, X., Wu, H., et al. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev. Ind. Pharm. 37:475-481, 2011.
8. Gaudana, R., Jwala, J., Boddu, S.H.S., & Mitra, A.K. Recent perspectives in ocular drug delivery. Pharm. Res. 26:1197-1216, 2009.
9. Mainardes, R.M., Urban, M.C., Cinto, P.O., et al. Colloidal carriers for ophthalmic drug delivery. Curr. Drug Targets. 6:363-371, 2005.
10. Hosoya, K.-I., Lee, V.H.L., & Kim, K.-J. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur. J. Pharm. Biopharm. 60:227-240, 2005.
11. Gunda, S., Hariharan, S., Mandava, N., & Mitra, A.K. Barriers in ocular drug delivery. In: Tombran-Tink, J., Barnstable, C.J., eds. Ocular Transporters in Ophthalmic Disease and Drug Delivery. New York: Humana Press; 2008; pp. 399-413.
12. Hornof, M., Toropainen, E., & Urtti, A. Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm. 60: 207-225, 2005.
13. Janoria, K.G., Gunda, S., Boddu, S.H.S, and Mitra, A.K. Novel approaches to retinal drug delivery. Expert Opin. Drug Deliv. 4:371-388, 2007.
14. Moshfeghia, A.A., & Peymanb, G.A. Micro-And nanoparticulates. Adv. Drug Deliv. Rev. 57:2047-2052, 2005.
15. Eljarrat-Binstock, E., Pe'er, J., & Domb, A.J. New techniques for drug delivery to the posterior eye segment. Pharm. Res. 27:530-543, 2010.
16. Mannermaa, E. In Vitro Model of Retinal Pigment Epithelium for Use in Drug Delivery Studies. Kuopio: University of Eastern Finland; 2010.
17. Duvvuri, S., Majumdar, S., & Mitra, A.K. Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther. 3:45-56, 2003.
18. Hsu, J. Drug delivery methods for posterior segment disease. Curr. Opin. Ophthalmol. 18:235-239, 2007.
19. Harder, B.B., von Baltz, S., Jonas, J.B., & Schlichtenbrede, F.C. Intravitreal bevacizumab for retinopathy of prematurity. J. Ocul. Pharmacol. Ther. 27:623-627, 2011.
20. Kolomeyer, A.M., Roy, M.S., & Chu, D.S. The use of intravitreal ranibizumab for choroidal neovascularization associated with vogt-koyanagi-harada syndrome. Case Rep. Med. 2011:747648, 2011.
21. Wadhwa, S., Paliwal, R., Paliwal, S.R., & Vyas, S.P. Nanocarriers in ocular drug delivery: an update review. Curr. Pharm. Des. 15:2724-2750, 2009.
22. Ausayakhun, S., Yuvaves, P., Ngamtiphakom, S., and Prasitsilp, J. Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir. J. Med. Assoc. Thai. 88:S15-S20, 2005.
23. Ambati, J., & Adamis, A.P. Transscleral drug delivery to the retina and choroid. Prog. Retin. Eye Res. 21:145-151, 2002.
24. Lee, S.B., Geroski, D.H., Prausnitz, M.R., & Edelhauser, H.F. Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp. Eye Res. 78:599-607, 2004.
25. Ghate, D., & Edelhauser, H.F. Ocular drug delivery. Expert Opin. Drug Deliv. 3:275-287, 2006.
26. Cheruvu, N.P.S., Ayalasomayajula, S.P., & Kompella, U.B. Retinal delivery of sodium fluorescein, budesonide & celecoxib following subconjunctival injection. Drug Deliv. Technol. 3:62-67, 2003.
27. Raghava, S., Hammond, M., & Kompella, U.B. Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv. 1:99-114, 2004.
28. Pitkänen, L., Ranta, V.P., Moilanen, H., & Urtti, A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci. 46:641-646, 2005.
29. Ambati, J., Gragoudas, E.S., Miller, J.W., et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. 41:1186-1191, 2000.
30. Geroski, D.H., & Edelhauser, H.F. Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. 52:37-48, 2001.
31. Yasukawa, T., Ogura, Y., Tabata, Y., Kimura, H., Wiedemann, P., & Honda, Y. Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res. 23:253-281, 2004.
32. Eljarrat-Binstock, E., Domb, A.J., Orucov, F., Frucht-Pery, J., and Pe'er, J. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr. Eye Res. 32:639-646, 2007.
33. Eljarrat-Binstock, E., Orucov, F., Frucht-Pery, J., Pe'er, J., and Domb, A.J. Methylprednisolone delivery to the back of the eye using hydrogel iontophoresis. J. Ocul. Pharm. Ther. 24:344-350, 2008.
34. Souied, E.H., Reid, S.N.M., Piri, N.I., Lerner, L.E., Nusinowitz, S., & Farber, D.B. Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration. Exp. Eye Res. 87:168-175, 2008.
35. Musch, D.C., Martin, D.F., Gordon, J.F., Davis, M.D., and Kuppermann, B.D. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N. Engl. J. Med. 337:83-90, 1997.
36. Jaffe, G.J., Martin, D., Callanan, D., Pearson, P.A., Levy, B., and Cornstock, T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 113:1020-1027, 2006.
37. Kane, F.E., Burdan, J., Cutino, A., & Green, K.E. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin. Drug Deliv. 5:1039-1046, 2008.
38. Kuno, N., & Fujii, S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drug Aging. 27: 117-134, 2010.
39. Kang Zhang, K., Hopkins, J.J., & Heier, J.S. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 108: 6241-6245, 2011.
40. Talcott, K.E., Ratnam, K., Sundquist, S.M., et al. Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest. Ophthalmol. Vis. Sci. 52:2219-2226, 2011.
41. Bakri, S.J., & Omar, A.F. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. J. Ocul. Pharmacol. Ther. 28:547-549, 2012.
42. Saishin, Y., Silva, R.L., Saishin, Y., et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest. Ophthalmol. Vis. Sci. 44:4989-4993, 2003.
43. Kompella, U.B., Bandi, N., & Ayalasomayajula, S.P. Subconjunctival nano-And microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. 44: 1192-1201, 2003.
44. Carrasquillo, K.G., Ricker, J.A., Rigas, I.K., Miller, J.W., Gragoudas, E.S., & Adamis, A.P. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic) acid microspheres. Invest. Ophthalmol. Vis. Sci. 44:290-299, 2003.
45. Ayalasomayajula, S.P., & Kompella, U.B. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharmacol. 511:191-198, 2005.
46. Loftsson, T., Hreinsdóttir, D., & Stefánsson, E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J. Pharm. Pharmacol. 59:629-635, 2007.
47. Camelo, S., Lajavardi, L., Bochot, A., et al. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol. Vis. 13:2263-2274, 2007.
48. Lajavardi, L., Camelo, S.l, Agnely, F., et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J. Control. Release. 139:22-30, 2009.
49. Zhang, R., He, R., Qian, J., Guon, J., Xue, K., & Yuan, Y.-F. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest. Ophthalmol. Vis. Sci. 51:3575-3582, 2010.
50. Reeves, B.C., Harding, S.P., Langham, J., et al. Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK. Health Technol. Assess. 16:1-200, 2012.
51. Kaiser, P.K., Boyer, D.S., Cruess, A.F., et al. Verteporfin plus ranibizumab for choroidal neovascularization in agerelated macular degeneration: twelve-month results of the DENALI Study. Ophthalmology. 119:1001-1010, 2012.
52. de Kozak, Y., Andrieux, K., Villarroya, H., et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. 34:3702-3712, 2004.
53. Irache, J.M., Merodio, M., Arnedo, A., Camapanero, M.A., Mirshashi, M., & Espuelas, S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev. Med Chem. 5:293-305, 2005.
54. Araújo, J., Nikoli, S., Egea, M.A., Souto, E.B., & García, M.L. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf. B Biointerfaces. 88:150-157, 2011.
55. Delgado, D., del Pozo-Rodríguez, A., Solinís, M.A., et al. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. Hum. Gene Ther. 23:345-355, 2012.
56. Frucht-Pery, J., Mechoulam, H., Siganos, C.S., Ever-Hadani, P., Shapiro, M., & Domb, A. Iontophoresis-gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe. Exp. Eye Res. 78:745-749, 2004.
57. Eljarrat-Binstock, E., Raiskup, F., Stepensky, D., Domb, A.J., and Frucht-Pery, J. Delivery of gentamicin to the rabbit eye by drug-loaded hydrogel iontophoresis. Invest. Ophthalmol. Vis. Sci. 45:2543-2548, 2004.
58. Jiang, J., Gill, H.S., Ghate, D., et al. Coated microneedles for drug delivery to the eye. Invest. Ophthalmol. Vis. Sci. 48: 4038-4043, 2007.
59. Maurice, D. Review: practical issues in intravitreal drug delivery. J. Ocul. Pharmacol. Ther. 17:393-401, 2001.
60. Guinedi, A.S., Mortada, N.D., Mansour, S., & Hathout, R.M. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int. J. Pharm. 306:71-82, 2005.
61. Bourges, J.L., Gautier, S.E., Delie, F., et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. 44:3562-3569, 2003.
62. Sahoo, S.K., Dilnawaz, F., & Krishnakumar, S. Nanotechnology in ocular drug delivery. Drug Discov. Today. 13:144-151, 2008.
63. Kothuri, M.K., Pinnamaneni, S., Das, N.G., & Das, S.K. Microparticles and nanoparticles in ocular drug delivery. In: Mitra, A.K., ed. Ophthalmic Drug Delivery Systems. NY: Informa Healthcare; 2003; pp. 437-466.
64. Diebold, Y., & Calonge, M. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res. 29:596-609, 2010.
65. Mehnert, W., & Mäder, K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev. 47:165-196, 2001.
66. Gasco, M.R. Method for producing solid lipid microspheres having a narrow size distribution. US5250236; 1993.
67. Müller, R.H., & Lucks, J.S. Medication vehicles made of solid lipid particle (solid lipid nanospheres SLN). EP0605497; 1996.
68. Joshi, M.D., & Müller, R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71:161-172, 2009.
69. Müller, R.H., Runge, S.A., Ravelli, V., Thünemann, A.F., Mehnert, W., & Souto, E.B. Cyclosporine-loaded solid lipid nanoparticles (SLN-): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 68:535-544, 2008.
70. Liu, J., Gong, T., Fu, H., et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 356:333-344, 2008.
71. Fang, J.Y., Fang, C.L., Liu, C.H., & Su, Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 70:633-640, 2008.
72. Sznitowska, M., Gajewska, M., Janicki, S., Radwanska, A., and Lukowskic, G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur. J. Pharm. Biopharm. 52:159-163, 2001.
73. Gokce, E.H., Sandri, G., Bonferoni, M.C., et al. Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int. J. Pharm. 364:76-86, 2008.
74. Sawant, K.K., & Dodiya, S.S. Recent advances and patents on solid lipid nanoparticles. Recent Pat. Drug Deliv. Formul. 2:120-135, 2008.
75. Pedersen, N., Hansen, S., Heydenreich, A.V., Kristensen, H.G., & Poulsen, H.S. Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur. J. Pharm. Biopharm. 62:155-162, 2006.
76. Asasutjarit, R., Lorenzen, S-I., Sirivichayakul, S., Ruxrungtham, K., Ruktanonchai, U., & Ritthidej, G.C. Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIVHugag transfection. Pharm. Res. 24:1098-1107, 2007.
77. Vighi, E., Ruozi, B., Montanari, M., Battini, R., & Leo, E. pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int. J. Pharm. 389:254-261, 2010.
78. Delgado, D., del Pozo-Rodríguez, A., Solinís, M.A., and Gascón, A.R. Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway. Eur. J. Pharm. Biopharm. 79:495-502, 2011.
79. Attama, A.A., Reichl, S., & Müller-Goymann, C.C. Sustained release and permeation of timolol from surfacemodified solid lipid nanoparticles through bioengineered human cornea. Curr. Eye Res. 34:698-705, 2009.
80. Dodiya, S.S., Chavhan, S.S., Sawant, K.K., & Korde, A.G. Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. J. Microencapsul. 28:515-527, 2011.
81. Venishetty, V.K., Chede, R., Komuravelli, R., Adepu, L., Sistla, R., & Diwan, P.V. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf. B Biointerfaces. 95:1-9, 2012.
82. Cavalli, R., Gasco, M.R., Chetoni, P., Burgalassi, S., and Saettone, M.F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 238:241-245, 2002.
83. Gallarate, M., Trotta, M., Battaglia, L., & Chirio, D. Cisplatin-loaded SLN produced by coacervation technique. J. Drug Del. Sci. Tech. 20:343-347, 2010.
84. Hu, L., Jia, H., Luo, Z., Liu, C., & Xing, Q. Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Pharmazie. 65:110-113, 2010.
85. Seyfoddin, A., & Al-Kassas, R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev. Ind. Pharm. 2012 [Epub ahead of print]; DOI: 10.3109/ 03639045.2012.665460.
86. Melike, Ü., & Gülgün, Y. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomed. 2:289-300, 2007.
87. Wissing, S.A., Kayser, O., & Müller, R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56:1257-1272, 2004.
88. Müller, R.H., Mäder, K., & Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery -A review of the state of the art. Eur. J. Pharm. Biopharm. 50:161-177, 2000.
89. Müller, R.H., Mehnert, W., & Lucks, J.-S. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41:62-69, 1995.
90. Zur Muhlen, A., & Mehnert, W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie. 53:552-555, 1998.
91. Puri, A., Loomis, K., Smith, B., et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 26:523-580, 2009.
92. Kaur, I.P., Rana, C., & Singh, H. Development of effective ocular preparations of antifungal agents. J. Ocul. Pharmacol. Ther. 24:481-493, 2008.
93. Müller, R.H., Radtke, M., & Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242:121-128, 2002.
94. Teeranachaideekul, V., Müller, R.H., & Junyaprasert, V.B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC) -Effects of formulation parameters on physicochemical stability. Int. J. Pharm. 340:198-206, 2007.
95. Radtke, M., Souto, E.B., & Müller, R.H. Nanostructured lipid carriers: a novel generation of solid lipid drug carriers. Pharm. Technol. Eur. 17:45-50, 2005.
96. Müller, R.H., Radtke, M., & Wissing, S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54:S131-S135, 2002.
97. Müller, R.H., & Olbrich, C. Lipid matrix-drug conjugates particle for controlled release of active ingredient. US6770299; 2004.
98. Olbrich, C., Gessner, A., Kayser, O., & Müller, R.H. Lipid-Drug-Conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target. 10:387-396, 2002.
99. Olbrich, C., Gessner, A., Schröder, W., Kayser, O., and Müller, R.H. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J. Control. Release. 96:425-435, 2004.
100. Paliwal, R., Rai, S., & Vyas, S.P. Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate. J. Biomed. Nanotechnol. 7:130-131, 2011.
101. Puglia, C., & Bonina, F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin. Drug Deliv. 9:429-441, 2012.
102. Ridolfi, D.M., Marcato, P.D., Justo, G.Z., Cordi, L., Machado, D., & Durán, N. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids Surf. B Biointerfaces. 93:36-40, 2012.
103. Attama, A.A., Reichl, S., & Müller-Goymann, C.C. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int. J. Pharm. 355:307-313, 2008.
104. Liu, D., Ge, Y., Tang, Y., et al. Solid lipid nanoparticles for transdermal delivery of diclofenac sodium: preparation, characterization and in vitro studies. J. Microencapsul. 27:726-734, 2010.
105. Souto, E.B., Doktorovova, S., Gonzalez-Mira, E., Egea, M.A., & Garcia, M.L. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr. Eye Res. 35:537-552, 2010.
106. Li, R., Jiang, S., Liu, D., et al. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J. Microencapsul. 28:134-141, 2011.
107. Almeida, A.J., & Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59:478-490, 2007.
108. Fonte, P., Andrade, F., Araújo, F., Andrade, C., Neves, Jd., & Sarmento, B. Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol. 508:295-314, 2012.
109. Siddiqui, A., Patwardhan, G.A., Liu, Y.Y., & Nazzal, S. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-AsGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells. Int. J. Pharm. 400:251-259, 2010.
110. Choi, S.H., Jin, S.E., Lee, M.K., et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur. J. Pharm. Biopharm. 68:545-554, 2008.
111. del Pozo-Rodríguez, A., Delgado, D., Solinís, M.A., et al. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int. J. Pharm. 385:157-162, 2010.
112. Doroud, D., Vatanara, A., Zahedifard, F., et al. Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J. Control. Release. 148:e105-e106, 2010.
113. Rudolph, C., & Rosenecker, J. Formation of solid lipid nanoparticle (SLN)-gene vector complexes for transfection of mammalian cells in vitro. Cold Spring Harb. Protoc. 2012:357-360, 2012.
114. Vighi, E., Montanari, M., Ruozi, B., Iannuccelli, V., & Leo, E. The role of protamine amount in the transfection performance of cationic SLN designed as a gene nanocarrier. Drug Deliv. 19:1-10, 2012.
115. Montana, G., Bondi, M.L., Carrotta, R., et al. Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug. Chem. 18:302-308, 2007.
116. Kim, H.R., Kim, I.K., Bae, K.H., Lee, S.H., Lee, Y., & Park, T.G. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm. 5:622-631, 2008.
117. Tao, W., Davide, J.P., Cai, M., et al. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol. Ther. 18:1657-1666, 2010.
118. Lobovkina, T., Jacobson, G.B., Gonzalez-Gonzalez, E., et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano. 5:9977-9983, 2011.
119. Corrias, F., & Lai, F. New methods for lipid nanoparticles preparation. Recent Pat. Drug Deliv. Formul. 5:201-213, 2011.
120. Schwarz, C., Mehnert, W., Lucks, J.S., & Müller, R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Control. Release. 30:83-96, 1994.
121. Bondi, M.L., Azzolina, A., Craparo, E.F., et al. Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery. J. Drug Target. 15:295-301, 2007.
122. Sjöström, B., Kaplun, A., Talmon, Y., & Cabane, B. Structures of nanoparticles prepared from Oil-in-Water emulsions. Pharm. Res. 12:39-48, 1995.
123. Battaglia, L., Trotta, M., Gallarate, M., Carlotti, M.E., Zarta, G.P., & Bargoni, A. Solid lipid nanoparticles formed by solvent-in-water emulsion-technique: Development and influences on insulin stability. J. Microencapsul. 24:672-684, 2007.
124. Jovanovic, N., Bouchard, A., Hofland, G.W., Witkamp, G-J., Crommelin, D., & Jiskoot, W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm. Res. 21:1955-1969, 2004.
125. Gallarate, M., Battaglia, L., Peira, E., & Trotta, M. Peptide-loaded solid lipid nanoparticles prepared through coacervation technique. Int. J. Chem. Eng. 2011 [Epub ahead of print]; DOI: 10.1155/2011/132435
126. Zhang, X., Pan, W., Gan, L., Zhu, C., Gan, Y., & Nie, S. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull. 56:1645-1650, 2008.
127. Charcosset, C., El-Harati, A., & Fessi, H. Preparation of solid lipid nanoparticles using a membrane contactor. J. Control. Release. 108:112-120, 2005.
128. Trotta, M., Cavalli, R., Trotta, C., Bussano, R., & Costa, L. Electrospray technique for solid lipid-based particle production. Drug Dev. Ind. Pharm. 36:431-438, 2010.
129. Parhi, R., & Suresh, P. Preparation and characterization of solid lipid nanoparticles-A review. Curr. Drug Discov. Technol. 9:2-16, 2012.
130. Müller, R.H., Shegokar, R., & Keck, C.M. 20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications. Curr. Drug Discov. Technol. 8:207-227, 2011.
131. Ekambaran, P., Sathali, A.H., & Priyanka, K. Solid lipid nanoparticles: a review. Sci. Rev. Chem. Commun. 2:80-102, 2012.
132. Müller, R.H., Runge, S., Ravelli, V., Mehnert, W., Thünemann, A.F., & Souto, E.B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 317:82-89, 2006.
133. Zhang, Q., Yie, G., Li, Y., Yang, Q., & Nagai, T. Studies on the cyclosporin A loaded stearic acid nanoparticles. Int. J. Pharm. 200:153-159, 2000.
134. Tiyaboonchai, W., Tungpradit, W., & Plianbangchang, P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int. J. Pharm. 337:299-306, 2007.
135. Koziara, J.M., Oh, J.J., Akers, W.S., Ferraris, S.P., and Mumper, R.J. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 22:1821-1828, 2005.
136. Quintanar-Guerrero, D., Tamayo-Esquivel, D., Ganem-Quintanar, A., Allémann, E., & Doelker, E. Adaptation and optimization of the emulsification-diffusion technique to prepare lipidic nanospheres. Eur. J. Pharm. Sci. 26:211-218, 2005.
137. Schubert, M.A., & Müller-Goymann, C.C. Solvent injection as a new approach for manufacturing lipid nanoparticles -evaluation of the method and process parameters. Eur. J. Pharm. Biopharm. 55:125-131, 2003.
138. Battaglia, L., & Gallarate, M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin. Drug Deliv. 9:497-508, 2012.
139. Chattopadhyay, P., Shekunov, B.Y., Yim, D., Cipolla, D., Boyd, B., & Farr, S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv. Drug Deliv. Rev. 59:444-453, 2007.
140. Salmaso, S., Elvassore, N., Bertucco, A., & Caliceti, P. Production of solid lipid submicron particles for protein delivery using a novel supercritical gas-Assisted melting atomization process. J. Pharm. Sci. 98:640-650, 2009.
141. Sebti, T., & Amighi, K. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur. J. Pharm. Biopharm. 63:51-58, 2006.
142. El-Harati, A.A., Charcosset, C., & Fessi, H. Influence of the formulation for solid lipid nanoparticles prepared with a membrane contactor. Pharm. Dev. Technol. 11:153-157, 2006.
143. Charcosset, C., El-Harati, A.A., & Fessi, H. A membrane contactor for the preparation of solid lipid nanoparticles. Desalination. 200:570-571, 2006.
144. Attama, A.A., Reichl, S., & Müller-Goymann, C.C. Sustained release and permeation of timolol from surfacemodified solid lipid nanoparticles through bioengineered human cornea. Curr. Eye Res. 34:698-705, 2009.
145. Basaran, E., Demirel, M., Sirmagül, B., & Yazan, Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J. Microencapsul. 27:37-47, 2010.
146. Shen, J., Sun, M., Ping, Q., Ying, Z., & Liu, W. Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology. 21:025101, 2010.
147. Shen, J., Deng, Y., Jin, X., Ping, Q., Su, Z., & Li, L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int. J. Pharm. 402:248-253, 2010.
148. Gonzalez-Mira, E., Nikolić, S., Calpena, A.C., Egea, M.A., Souto, E.B., & García, ML. Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels. J. Pharm. Sci. 101:707-725, 2012.
149. Luo, Q., Zhao, J., Zhang, X., & Pan, W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int. J. Pharm. 403:185-191, 2011.
150. Tian, B., Luo, Q., Song, S., et al. Novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan for efficient ocular delivery. J. Pharm. Sci. 101:1040-1049, 2012.
151. Jonas, J.B. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 38:218-245, 2006.
152. Araújo, J., Gonzalez-Mira, E., Egea, M.A., Garcia, M.L., and Souto, E.B. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int. J. Pharm. 393:168-176, 2010.
153. del Pozo-Rodríguez, A., Delgado, D., Solinís, M.A., and Pedraz, J.L. Solid lipid nanoparticles for retinal gene therapy: Transfection and intracellular trafficking in RPE cells. Int. J. Pharm. 360:177-183, 2008.
154. Bainbridge, J.W., Smith, A.J., Barker, S.S., et al. Effect of gene therapy on visual function in Leber's Congenital Amaurosis. N. Engl. J. Med. 358:2231-2239, 2008.
155. Maguire, A.M., High, K.A., Auricchio, A., et al. Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 374:1597-1605, 2009.
156. Bennett, J., Ashtari, M., & Wellman, J. AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med. 4:120ra15, 2012.
157. Kumar-Singh, R. Barriers for retinal gene therapy: separating fact from fiction. Vis. Res. 48:1671-1680, 2008.
158. Provost, N., Le Meur, G., Weber, M., et al. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol. Ther. 11:275-283, 2005.
159. del Pozo-Rodríguez, A., Delgado, D., Solinís, M.A., Gascón, A.R., & Pedraz, J.L. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm. 339:261-268, 2007.
160. Delgado, D., Gascón, A.R., del Pozo-Rodríguez, A., et al. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int. J. Pharm. 425:35-43, 2012.
161. del Pozo-Rodríguez, A., Solinís, M.A., Gascón, A.R., and Pedraz, J.L. Short-And long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur. J. Pharm. Biopharm. 71:181-189, 2009.
162. del Pozo-Rodriguez, A., Pujals, S., Delgado, D., et al. A proline-rich peptide improves cell transfection of solid lipid nanoparticles-based non-viral vectors. J. Control. Release. 133:52-59, 2009.
163. Boulanger, C., Di Giorgio, C., & Vierling, P. Synthesis of acridine-nuclear localization signal (NLS) conjugates and evaluation of their impact on lipoplex and polyplex-based transfection. Eur. J. Med. Chem. 40:1295-1306, 2005.
164. Biegeleisen, K. The probable structure of the protamine-DNA complex. J. Theor. Biol. 241:533-540, 2006.
165. Agarwal, A., Gupta, U., Asthana, A., & Jain, N.K. Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent. Biomaterials. 30:3588-3596, 2009.
166. Gascón, A.R., Solinís, M.A., del Pozo-Rodríguez, A., Delgado, D., & Pedraz, J.L. Lipid nanoparticles for gene therapy. ES2351756B1 2011.
167. Mooy, C.M., Van Den Born, L.I., Baarsma, S., et al. (2002). Hereditary X-linked juvenile retinoschisis: a review of the role of Müller cells. Arch. Ophthalmol. 120:979-984, 2002.